Loading...
Since 2023, the CDC recommendation for respiratory syncytial virus (RSV) vaccine has evolved from a single dose for people aged ≥60 to the current recommendation of a single dose for people aged ≥75 and those aged 50 to 74 at increased risk for severe RSV disease. Clinical trials have suggested that a single dose of RSV vaccine provides at least 2 years of protection, but the trials skewed young and excluded immunocompromised patients.
To determine how effective a single dose is over two consecutive seasons in a broader population, researchers studied U.S. veterans aged 60 and older. Using statistical methods to mimic a clinical trial, they matched 300,000 veterans who received a dose of protein-based RSV vaccine during the 2023–2024 …
